Eli Lilly and Horizon Therapeutics contributed to the life sciences venture firm's Forbion Growth Opportunities Fund, which will make late-stage investments.
Netherlands-based venture capital firm Forbion has reached the €185m ($210m) first close of its latest fund with backing from limited partners including pharmaceutical companies Eli Lilly and Horizon Therapeutics.
Forbion Growth Opportunities Fund’s other LPs include KfW Capital, a subsidiary of development bank KfW, as well as Pantheon, European Investment Fund (EIF), Belgian Growth Fund and New Waves Investments.
Founded in 2006, Forbion invests in life sciences technology developers based in Europe. Its latest vehicle will provide late-stage funding for…
